Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $228,476 - $452,382
-5,936 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $345,890 - $706,324
5,936 New
5,936 $431,000
Q2 2020

Aug 14, 2020

SELL
$11.14 - $22.87 $276,539 - $567,724
-24,824 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$9.44 - $15.58 $234,338 - $386,757
24,824 New
24,824 $304,000
Q4 2018

Feb 14, 2019

SELL
$11.39 - $27.13 $105,562 - $251,440
-9,268 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$25.78 - $32.6 $238,929 - $302,136
9,268 New
9,268 $265,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.7B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.